These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8642690)

  • 1. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.
    Gauduin MC; Allaway GP; Maddon PJ; Barbas CF; Burton DR; Koup RA
    J Virol; 1996 Apr; 70(4):2586-92. PubMed ID: 8642690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
    Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
    AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
    Mo H; Stamatatos L; Ip JE; Barbas CF; Parren PW; Burton DR; Moore JP; Ho DD
    J Virol; 1997 Sep; 71(9):6869-74. PubMed ID: 9261412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
    Lagenaur LA; Villarroel VA; Bundoc V; Dey B; Berger EA
    Retrovirology; 2010 Feb; 7():11. PubMed ID: 20158904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.
    Allaway GP; Davis-Bruno KL; Beaudry GA; Garcia EB; Wong EL; Ryder AM; Hasel KW; Gauduin MC; Koup RA; McDougal JS
    AIDS Res Hum Retroviruses; 1995 May; 11(5):533-9. PubMed ID: 7576908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
    Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
    Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
    D'Souza MP; Livnat D; Bradac JA; Bridges SH
    J Infect Dis; 1997 May; 175(5):1056-62. PubMed ID: 9129066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.
    Klasse PJ; McKeating JA
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):595-604. PubMed ID: 8369164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M; Moore JP; Broersen S; Schuitemaker H
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
    Sullivan N; Sun Y; Li J; Hofmann W; Sodroski J
    J Virol; 1995 Jul; 69(7):4413-22. PubMed ID: 7769703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.
    Beaumont T; Broersen S; van Nuenen A; Huisman HG; de Roda Husman AM; Heeney JL; Schuitemaker H
    J Virol; 2000 Sep; 74(17):7699-707. PubMed ID: 10933675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.